Deflazacort
Orphan DrugFDA Approved
Description
Deflazacort is a corticosteroid used to treat Duchenne muscular dystrophy. It works by reducing inflammation and suppressing the immune system.
Indications & Therapeutic Use
autosomal recessive limb-girdle muscular dystrophy type 2U
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Deflazacort
| Generic Name | Deflazacort |
| Brands | 1 brand available |
| Active Ingredient | Deflazacort |
| Drug Class | autosomal recessive limb-girdle muscular dystrophy type 2U |
| Manufacturer | Marathon Pharmaceuticals |
| Dosage Forms | Oral tablet, Oral suspension |
| Medical Code | H02AB04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00850449 |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes